ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Value of threshold growth for the diagnosis of hepatocellular carcinoma using LI-RADS.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe utility of threshold growth (TG) in hepatocellular carcinoma (HCC) imaging remains contentious across major guidelines. This study aimed to investigate the diagnostic implications of TG in HCC diagnosis using the criteria set by the Liver Imaging Reporting and Data System (LI-RADS).
methodsIn this single-center retrospective study, three radiologists independently evaluated pre-transplantation hepatobiliary agent-enhanced MR images and prior CT/MR images using LI-RADS v2018 in consecutive patients who underwent liver transplantation between January 2010 and November 2022. TG was defined as a ≥ 50% size increase in ≤ 6 months. Explanted livers served as reference standards. Frequencies of TG between HCCs and non-HCCs were compared using Fisher's exact test, and interobserver agreement was assessed using Fleiss κ statistics. The diagnostic performance of LI-RADS category 5 in the diagnosis of HCC was assessed with and without considering TG as a major feature. McNemar tests were used to compare results.
resultsThe cohort included 158 patients (mean age, 59.1 ± 7.5 years; 130 males) with 280 observations (207 HCCs, 5 non-HCC malignancies, and 68 benign lesions). TG was identified in 44 (15.7%) observations. Interobserver agreement on TG was moderate (κ = 0.280). Incorporating TG as a major feature significantly enhanced the sensitivity of LI-RADS category 5 in diagnosing HCC (33.8% vs. 40.6%, p < 0.001) without compromising specificity (100.0% vs. 94.5%, p = 0.125).
conclusionsIncorporating TG as a major criterion in LI-RADS category 5 enhanced the diagnostic sensitivity for HCC in liver transplant candidates with minimal impact on specificity. However, TG demonstrated a variable interobserver agreement.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.